Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

65
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
65

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Cerebral Microbleeds on Tau-Associated Cognitive and Structural Decline.

Neurology·2025
Same author

Emerging Concepts of Targeted Protein Degrader Technologies via Lysosomal Pathways.

International journal of molecular sciences·2025
Same author

Synthesis, biological evaluation, and <i>in silico</i> studies of lantadene-derived pentacyclic triterpenoids as anticancer agents targeting IKK-β.

Journal of biomolecular structure & dynamics·2024
Same author

Diverging Relationships among Amyloid, Tau, and Brain Atrophy in Early-Onset and Late-Onset Alzheimer's Disease.

Yonsei medical journal·2024
Same author

Review of Current Treatment Intensification Strategies for Prostate Cancer Patients.

Cancers·2023
Same author

Repurposing of conformationally-restricted cyclopentane-based AKT-inhibitors leads to discovery of potential and more selective antileishmanial agents than miltefosine.

Bioorganic chemistry·2023

Related Experiment Video

Updated: May 22, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

76

PET tracer development for imaging α-synucleinopathies.

Mohammad Maqusood Alam1, Sun Hak Lee1, Sobia Wasim1

  • 1Neuroscience Research Institute, Gachon University, Incheon, 20565, Republic of Korea.

Archives of Pharmacal Research
|April 14, 2025
PubMed
Summary

Developing alpha-synuclein (α-synuclein) positron emission tomography (PET) tracers is crucial for diagnosing and monitoring neurodegenerative diseases like Parkinson's disease. This review highlights advancements in PET imaging for α-synucleinopathies.

Keywords:
NeurodegenerationParkinson’s diseaseRadiotracerα-Synuclein aggregatesα-Synucleinopathies

More Related Videos

Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue FACS-RTT to Determine the Cellular Origin of Radioactive Signal
12:04

Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue FACS-RTT to Determine the Cellular Origin of Radioactive Signal

Published on: September 10, 2021

2.3K
Detection of Disease-associated &#945;-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated &#945;-synuclein
12:01

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

10.7K

Related Experiment Videos

Last Updated: May 22, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

76
Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue FACS-RTT to Determine the Cellular Origin of Radioactive Signal
12:04

Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue FACS-RTT to Determine the Cellular Origin of Radioactive Signal

Published on: September 10, 2021

2.3K
Detection of Disease-associated &#945;-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated &#945;-synuclein
12:01

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

10.7K

Area of Science:

  • Neuroscience
  • Radiochemistry
  • Molecular Imaging

Background:

  • Abnormal alpha-synuclein (α-synuclein) aggregation defines α-synucleinopathies, including Parkinson's disease (PD) and multiple system atrophy (MSA).
  • These conditions involve targeted neurodegeneration and Lewy body pathology, contributing to disease progression.
  • Current diagnostic and therapeutic strategies for α-synucleinopathies are limited by the lack of specific biomarkers.

Purpose of the Study:

  • To review the current state of α-synuclein positron emission tomography (PET) tracer development.
  • To discuss the potential of PET imaging in early diagnosis, drug development, and disease monitoring for α-synucleinopathies.
  • To explore future directions in the field of α-synuclein PET imaging.

Main Methods:

  • Focuses on the design and application of α-synuclein-targeted radiolabeled probes for in vivo imaging.
  • Utilizes positron emission tomography (PET) as a non-invasive imaging modality.
  • Summarizes recent research and ongoing efforts in developing selective PET tracers.

Main Results:

  • α-synuclein PET tracers target fibrillar α-synuclein aggregates, enabling visualization of neuropathology.
  • PET imaging offers a pathway for early diagnosis and assessment of treatment efficacy in α-synucleinopathies.
  • Significant progress has been made in understanding PD mechanisms through PET biomarker advancements.

Conclusions:

  • Development of selective α-synuclein PET tracers is essential for clinical applications in diagnosing and managing α-synucleinopathies.
  • In vivo detection of α-synuclein aggregates via PET holds promise for accelerating drug discovery and improving patient care.
  • Continued research in PET tracer development is critical for advancing the understanding and treatment of these neurodegenerative disorders.